COVID-19 vaccines are moving toward clinical trials
Drug developers are moving their experimental vaccines for COVID-19 into clinical trials at a frenetic pace. Trials for five such vaccines have begun in China. Two are being tested in the US, with a third slated to start this month. And trials of two more are due to begin in the UK and Australia in the coming weeks.
“Everything from basic science to clinical science is progressing at a pace faster than ever before—and very appropriately given the grave nature of the current global crisis,” says Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and Harvard University School of Medicine.
The World Health Organization says at least 70 COVID-19 vaccines are in development, while scientists at the Coalition for Epidemic Preparedness Innovations (CEPI) have counted 115.
On April 9, the World Health Organization announced that it is planning an international study, the SOLIDARITY vaccine trial, which will assess and compare multiple COVID-19 vaccines with each other and a single placebo arm.
Looking for chemical products? Let suppliers reach out to you!
2026-07-05
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
GlaxoSmithKline Pharmaceuticals Reports 11% Rise in Q1 Profit Driven by Strong Demand for Vaccines
-
How far behind is the vaccine industry?
-
Global Vaccine Market Rises to the TopAgain
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease
-
The domestic nine-valent HPV vaccine race is underway: These companies' vaccines have entered the clinical phase three stage
-
Twenty-five COVID-19 Vaccines In China Enter Stages Of Clinical Trials
-
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest 120 Million US Dollars
-
FDA Approves First New Measles, Mumps and Rubella Vaccine in 50 Years
Recommend Reading
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Glenmark Targets 10–15 Percent CAGR in India by Shifting to High-Margin Drugs AbbVie Deal and New Launches Boost Outlook
-
Wall Street Predicts New Obesity Pills Will Be Priced Near $1000 Like Wegovy and Zepbound Supply and Competition Pressures Mount
-
Haryana’s Drug Crackdown Gets Massive Public Support State Launches Podcast to Boost Community Involvement
-
Returning to Fundamentals: The Core Drivers Behind the Etylene Glycol Pullback on March 31
-
Weak Demand Leads to Slight Decline in Ammonium Sulfate Prices (8.18-8.22)
-
Zoledronic Acid: Uses, Mechanism, and Side Effects
-
March Ethylene Oxide Prices Soar to a Four-Year High in China
-
China Phenol Market Dominated by Rising Trend (8.15-22)